Preventing Long Covid with Metformin
Clinical Infectious Diseases, Jan. 2026
Link to full journal paper:
Paper · Clin Infect Dis · 2026Preventing Long COVID With Metformin.academic.oup.com
Quoted:
“In summary, 2 large, randomized, placebo-controlled clinical trials [COVID-OUT & ACTIV-6] in highly relevant populations show that starting metformin at the time of acute infection with SARS-CoV-2 is safe and lowers the risk of developing long COVID. Both trials enrolled after the Omicron variant appeared, enrolled adults with prior immunity, and enrolled adults considered to be low, standard, and high-risk. Both trials have been validated in target trial analyses of similar populations. There are no drug–drug interactions that prevent someone from taking both metformin and therapies currently listed in guidelines. Adding metformin to clinical treatment guidelines for nonhospitalized adults with acute SARS-CoV-2 infection would likely help disseminate the data to more individuals who match the populations in these studies (Figure 1).”
#metforminHD #covidHD #longcovidHD #metformincovidHD #covidoutHD #activ6HD
A decades-old diabetes drug may be quietly reshaping the long-COVID story, not by treating symptoms, but by stopping them before they begin.
For years, long COVID has felt frustratingly inevitable, a lingering shadow after infection, with few proven ways to prevent it. But a new review published in Clinical Infectious Diseases suggests a surprising contender: metformin, one of the most widely prescribed and affordable diabetes drugs in the world.
Researchers from the University of Minnesota analyzed multiple randomized clinical trials alongside large electronic health record studies. Across this growing body of evidence, one pattern keeps reappearing: people who started metformin during or shortly after acute COVID-19 infection had a 40–60% lower risk of developing long COVID.
Crucially, this wasn’t about treating long COVID after it sets in. The studies focused on prevention. The earliest trial, the COVID-OUT study, found a 41% reduction in clinician-diagnosed long COVID. Later trials broadened participation beyond obesity and first-time infections, and the protective effect held up in real-world data. Replication, the gold standard of science, is now the headline.
There’s another twist. Metformin also appears to lower viral load faster during acute infection, with some patients reaching undetectable levels days earlier, a clue that early viral control may shape long-term outcomes.
Despite its promise, uptake has been slow. Metformin doesn’t look like an antiviral. Yet it’s low-cost, widely available, and compatible with treatments like Paxlovid. Sometimes, the most powerful tools are hiding in plain sight.
If a safe, generic drug could cut your long-COVID risk in half, would you want it offered routinely after infection?
Source: Carolyn T Bramante, David R Boulware, Preventing Long COVID With Metformin, Clinical Infectious Diseases, 2026
